JanetChandlerDuboisMD

Dermatology • Austin, TX

Physician

Join to view full profile

Dr. Dubois is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Dubois' full profile

Already have an account?

Office
8140 North Mopac
Building 3, Suite 120
Austin, TX 78759
Phone+1 512-349-9889

Fax+1 512-349-9559
Is this information wrong?

Education & Training

Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Dermatology, 1988 - 1991
Case Western Reserve University/University Hospitals Cleveland Medical CenterInternship, Internal Medicine, 1987 - 1988
The University of Texas Health Science Center at San AntonioClass of 1987

Certifications & Licensure

TX State Medical License 1995 - 2025
WA State Medical License 1991 - 1994
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Top MD Consumers Checkbook
Super Doctor SuperDoctors.com

Clinical Trials

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis Start of enrollment: 2014 Jan 01
Completed
Phase 2
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis Start of enrollment: 2014 Apr 01
Completed
Phase 2
Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis Start of enrollment: 2014 Jun 01
Completed
Phase 2
A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris Start of enrollment: 2015 Apr 01
Completed
Phase 2
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Dec 01
Completed
Phase 3
Study of Glycopyrronium in Axillary Hyperhydrosis Start of enrollment: 2015 Jul 01
Completed
Phase 3
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis Start of enrollment: 2015 Aug 01
Completed
Phase 3
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2) Start of enrollment: 2016 Feb 01
Completed
Phase 2
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp Start of enrollment: 2017 Mar 01
Withdrawn
Phase 3
MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 Start of enrollment: 2019 Jun 27
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, Javier Alonso-Llamazares, Neal Bhatia, Janet DuBois, Seth B Forman, Melinda Gooderham, Lawrence Green, Scott T Guenth...> ;Journal of the American Academy of Dermatology. 2024 May 1
DMT310, a novel once-weekly topical treatment for patients with moderate-to-severe acne vulgaris: Results of a phase 2b randomized, double-blind, placebo-controlled tr...
Lawrence F Eichenfield, Janet C DuBois, Michael H Gold, Christopher J Nardo, Zoe D Draelos> ;Journal of the American Academy of Dermatology. 2023 Nov 1
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, Michael Bukhalo, Alim R Devani, Zoe D Draelos, Janet DuBois, Melinda J Gooderham, Steven E Kempers, Edward Lain, ...> ;The British Journal of Dermatology. 2023 Sep 15
2 citations
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
Matthew J Zirwas, Zoe D Draelos, Janet DuBois, Leon H Kircik, Angela Y Moore, Linda Stein Gold, Javier Alonso-Llamazares, Michael Bukhalo, Suzanne Bruce, Kimmie Eads, ...> ;JAMA Dermatology. 2023 Jun 1
16 citations
Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics.
John E. Jett, Michael McLaughlin, Mark S. Lee, Lawrence Charles Parish, Janet DuBois, Tooraj Joseph Raoof, Glenn Tabolt, Timothy Wilson, Matthew C. Somerville, Wayne D...> ;American Journal of Clinical Dermatology. 2021 Oct 28
3 citations
Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
Janet DuBois, Suzanne Bruce, Daniel Stewart, Steven Kempers, Christy Harutunian, Terry Boodhoo, Amy Weitzenfeld, Joan-En Chang-Lin> ;Clinical, Cosmetic and Investigational Dermatology. 2021 Oct 15
3 citations
Subject Satisfaction with Trifarotene 50 μg/g Cream in the Treatment of Facial and Truncal Acne Vulgaris: A Case Series
Sandra Marchese Johnson, Rajeev Chavda, Janet DuBois> ;Dermatology and Therapy. 2020 Jul 4
10 citations
Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial
Brandon Kirsch, Stacy Smith, Joel L. Cohen, Janet DuBois, Lawrence Green, Leslie Baumann, Neal Bhatia, David M. Pariser, Ping-Yu Liu, Deepak Chadha, Patricia S. Walker> ;Journal of the American Academy of Dermatology. 2020 Jun 1
3 citations
WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29...
Linda Stein-Gold, Leon H Kircik, Zoe Diane Draelos, Philip Werschler, Janet DuBois, Edward Lain, Leslie Baumann, David J. Goldberg, Joely Kaufman, Emil Tanghetti, Nanc...> ;Journal of the American Academy of Dermatology. 2018 Feb 4
8 citations
A-101, a Proprietary Topical Formulation of High-Concentration Hydrogen Peroxide Solution: A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the ...
Janet Dubois, Michael Jarratt, Brian Beger, Mark Bradshaw, Christopher Powala, Stuart D. Shanler> ;Dermatologic Surgery. 2017 Sep 1
Join now to see all

Press Mentions

Promising SK Drug’s Trials Enter Final PhasesMarch 3rd, 2015
Vial Launches Innovative Dermatology CRO January 27th, 2022
Safety of Hydrogen Peroxide Topical Solution 40% and 45% (w/w) in Patients with Seborrheic Keratoses on the Trunk, Extremities, and Face: Results of a Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group StudyAugust 21st, 2019